Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $3.25 Average Price Target from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $3.1667.

Several brokerages recently commented on INO. Zacks Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 12th. Jefferies Financial Group raised Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and raised their price target for the company from $1.80 to $3.00 in a research report on Thursday, August 13th. Piper Sandler reiterated an “overweight” rating and issued a $4.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. HC Wainwright reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Thursday, August 13th. Finally, Wall Street Zen upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Hedge funds have recently modified their holdings of the business. AQR Capital Management LLC acquired a new stake in shares of Inovio Pharmaceuticals in the first quarter worth $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in Inovio Pharmaceuticals in the 2nd quarter valued at $234,000. Jane Street Group LLC boosted its holdings in Inovio Pharmaceuticals by 221.2% in the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 27,329 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Inovio Pharmaceuticals by 1,667.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 61,516 shares during the last quarter. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Stock Up 8.3%

Shares of INO stock opened at $1.30 on Thursday. Inovio Pharmaceuticals has a 12 month low of $0.56 and a 12 month high of $2.98. The company has a market cap of $134.42 million, a PE ratio of -1.43 and a beta of 1.52. The business’s 50 day moving average is $1.03 and its two-hundred day moving average is $1.29.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. As a group, equities analysts expect that Inovio Pharmaceuticals will post -0.72 EPS for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.